For example, a Phase III trial (NCT03258931) comparing crenolanib with midostaurin following induction chemotherapy and consolidation therapy is ongoing in newly diagnosed FLT3‐mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.